7464-52-0

Basic information

• Product Name: 4-methoxy-N-(4-nitrophenyl)benzamide
• Synonyms: benzamide, 4-methoxy-N-(4-nitrophenyl)-
• CAS NO: 7464-52-0
• Molecular Formula: C₁₄H₁₂N₂O₄
• Molecular Weight: 272.2561
• Mol File: 7464-52-0.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 377.3°C at 760 mmHg
• Flash Point: 182°C
• Density: 1.333g/cm³
• Vapor Pressure: 6.8E-06mmHg at 25°C
• Refractive Index: 1.645
• CAS DataBase Reference: 4-methoxy-N-(4-nitrophenyl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-methoxy-N-(4-nitrophenyl)benzamide(7464-52-0)
• EPA Substance Registry System: 4-methoxy-N-(4-nitrophenyl)benzamide(7464-52-0)

Safety Data

• Hazardous Substances Data: 7464-52-0(Hazardous Substances Data)

Upstream product

• 100-07-2 4-methoxy-benzoyl chloride 
• 100-01-6 4-nitro-aniline 
• 3424-93-9 4-methoxyphenylacetamide 
• 98-95-3 nitrobenzene 
• 586-78-7 para-nitrophenyl bromide 
• 1516-60-5 4-nitrophenyl azide 
• 7465-88-5 4-methoxy-N-phenylbenzamide 
• 62-53-3 aniline 
• 100-09-4 4-methoxybenzoic acid 
• 123-11-5 4-methoxy-benzaldehyde 
• 61166-15-2 1-(p-methoxybenzoyl)-3-methylimidazolium chloride 
• 38968-72-8 4-Methoxy-N-phenyl-benzimidoyl chloride 

Downstream Products

• 23600-43-3 N?(4?aminophenyl)?4?methoxybenzamide 
• 1017572-85-8 (Z)-N-(1-(4-methoxyphenyl)-3-(trimethylsilyl)prop-2-ynylidene)-4-nitroaniline 
• 21010-34-4 4-methoxy-N-(4-nitrophenyl)benzothioamide 

Relevant articles and documents

Design, synthesis and molecular modeling study of certain VEGFR-2 inhibitors based on thienopyrimidne scaffold as cancer targeting agents

Different series of novel thieno [2,3-d]pyrimidine derivative (9a-d,10a-f,l,m and 15a-m) were designed, synthesized and evaluated for their ability to in vitro inhibit VEGFR-2 enzyme. Also, the cytotoxicity of the final compounds was tested against a panel of 60 different human cancer cell lines by NCI. The VEGFR-2 enzyme inhibitory results revealed that compounds 10d, 15d and 15 g are among the most active inhibitors with IC50 values of 2.5, 5.48 and 2.27 μM respectively, while compound 10a remarkably showed the highest cell growth inhibition with mean growth inhibition (GI) percent of 31.57%. It exhibited broad spectrum anti-proliferative activity against several NCI cell lines specifically on human breast cancer (T7-47D) and renal cancer (A498) cell lines of 85.5% and 77.65% inhibition respectively. To investigate the mechanistic aspects underlying the activity, further biological studies like flow cytometry cell cycle together with caspase-3 colorimetric assays were carried on compound 10a. Flow cytometric analysis on both MCV-7 and PC-3 cancer cells revealed that it induced cell-cycle arrest in the G0-G1phase and reinforced apoptosis via activation of caspase-3. Furthermore, molecular modeling studies have been carried out to gain further understanding of the binding mode in the active site of VEGFR-2 enzyme and predict pharmacokinetic properties of all the synthesized inhibitors.

Copper-Catalyzed Direct Nitration on Aryl C-H Bonds by Concomitant Azidation-Oxidation with TMS Azide and TBHP under Aerobic Conditions

An unprecedented copper-catalyzed in situ azidation-oxidation for the nitration of anilides and sulfonamides has been developed by direct CAr-H functionalization. This novel and efficient nitration protocol is achieved employing TMSN3 and TBHP without the exclusion of air or moisture. The synthetic applications of the 2-nitroanilides have been explored.

Synthesis and biological evaluation of 1-(2-aminophenyl)-3-arylurea derivatives as potential EphA2 and HDAC dual inhibitors

A series of 1-(2-aminophenyl)-3-arylurea novel derivatives were synthesized and evaluated against Ephrin type-A receptor 2 (EphA2) and histone deacetylases (HDACs) kinase. Most of the compounds exhibited inhibitory activity against EphA2 and HDAC. The antiproliferative activities were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (thiazolyl blue, tetrazolium blue) against the human cancer cell lines HCT116, K562 and MCF7. Compounds 5a and b showed the most potent inhibitory activity against EphA2 and HDAC. However, compound 5b exhibited higher potency against HCT116 (IC50=5.29 μM) and MCF7 (IC50=7.42 μM). 1-(2-Aminophenyl)-3-arylurea analogues may serve as new EphA2-HDAC dual inhibitors.